These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21937987)

  • 41. Time-dependent interaction of ritonavir in chronic use: the power balance between inhibition and induction of P-glycoprotein and cytochrome P450 3A.
    Fukushima K; Kobuchi S; Mizuhara K; Aoyama H; Takada K; Sugioka N
    J Pharm Sci; 2013 Jun; 102(6):2044-2055. PubMed ID: 23589366
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure.
    Mathias AA; West S; Hui J; Kearney BP
    Clin Pharmacol Ther; 2009 Jan; 85(1):64-70. PubMed ID: 18815591
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation.
    Nguyen AN; Hoffman JT; Tsunoda SM; Jang IJ; Ma JD
    Int J Clin Pharmacol Ther; 2012 Jul; 50(7):468-75. PubMed ID: 22541751
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.
    Kirby BJ; Collier AC; Kharasch ED; Whittington D; Thummel KE; Unadkat JD
    Drug Metab Dispos; 2011 Jun; 39(6):1070-8. PubMed ID: 21406602
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole.
    Hohmann N; Kocheise F; Carls A; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Clin Pharmacokinet; 2016 Dec; 55(12):1535-1545. PubMed ID: 27236320
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.
    Chenel M; Bouzom F; Cazade F; Ogungbenro K; Aarons L; Mentré F
    J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):661-81. PubMed ID: 19130187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam.
    Katzenmaier S; Markert C; Mikus G
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1137-41. PubMed ID: 20680253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers.
    Ancrenaz V; Déglon J; Samer C; Staub C; Dayer P; Daali Y; Desmeules J
    Basic Clin Pharmacol Toxicol; 2013 Feb; 112(2):132-7. PubMed ID: 22900583
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity.
    Lee LS; Bertino JS; Nafziger AN
    J Clin Pharmacol; 2006 Feb; 46(2):229-34. PubMed ID: 16432275
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decreased Cytochrome P450 3A activity in palliative patients with haematological diseases: Potential impact on supportive drug therapies.
    Geist MJP; Siller N; Egerer G; Bardenheuer H; Burhenne J; Mikus G
    Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):117-122. PubMed ID: 30916851
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.
    Kharasch ED; Hoffer C; Whittington D; Walker A; Bedynek PS
    Anesthesiology; 2009 Mar; 110(3):660-72. PubMed ID: 19225389
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis.
    Knox TA; Oleson L; von Moltke LL; Kaufman RC; Wanke CA; Greenblatt DJ
    J Acquir Immune Defic Syndr; 2008 Dec; 49(4):358-68. PubMed ID: 19186349
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation.
    Vanhove T; Annaert P; Knops N; de Loor H; de Hoon J; Kuypers DRJ
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):50-55. PubMed ID: 29989304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Semisimultaneous Midazolam Administration to Evaluate the Time Course of CYP3A Activation by a Single Oral Dose of Efavirenz.
    Mikus G; Heinrich T; Bödigheimer J; Röder C; Matthee AK; Weiss J; Burhenne J; Haefeli WE
    J Clin Pharmacol; 2017 Jul; 57(7):899-905. PubMed ID: 28194792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.
    Kharasch ED; Francis A; London A; Frey K; Kim T; Blood J
    Clin Pharmacol Ther; 2011 Jul; 90(1):100-8. PubMed ID: 21562488
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Daily honey consumption does not change CYP3A activity in humans.
    Fetzner L; Burhenne J; Weiss J; Völker M; Unger M; Mikus G; Haefeli WE
    J Clin Pharmacol; 2011 Aug; 51(8):1223-32. PubMed ID: 21148046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins.
    Loos NHC; Beijnen JH; Schinkel AH
    Biomed Pharmacother; 2023 Jun; 162():114636. PubMed ID: 37004323
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers.
    Huppertz A; Ott C; Bruckner T; Foerster KI; Burhenne J; Weiss J; Zorn M; Haefeli WE; Czock D
    Clin Pharmacol Ther; 2019 Dec; 106(6):1290-1298. PubMed ID: 31152598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice.
    Loos NHC; Martins MLF; de Jong D; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
    Mol Pharm; 2023 May; 20(5):2477-2489. PubMed ID: 36976574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life.
    Olkkola KT; Palkama VJ; Neuvonen PJ
    Anesthesiology; 1999 Sep; 91(3):681-5. PubMed ID: 10485779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.